Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Diseases: cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, renal cell carcinoma.

Part B (Accruing now): up to 15 patients in each disease will be enrolled and evaluated for safety, immunogenicity, and antitumor activity of GEN-009. Patients will receive GEN-009 with PD-1 inhibitor at the approved dose and schedule.

PATIENTS NEED TO SIGN CONSENT BEFORE STARTING PD-1 INHIBITOR THERAPY

Participate in a Clinical Trial

Learn More